Portal de Periódicos da CAPES

Mycophenolate Mofetil Treatment for IgA Nephropathy: A Meta-Analysis

2008; Karger Publishers; Volume: 29; Issue: 5 Linguagem: Inglês

10.1159/000168483

1421-9670

Gaosi Xu, Weiping Tu, Dongfeng Jiang, Chengyun Xu,

Platelet Disorders and Treatments

<i>Background:</i> Worldwide, IgA nephropathy (IgAN) is the most common type of glomerulonephritis. Mycophenolate mofetil (MMF) is relatively selective for lymphocytes and inhibits antibody production by B cells more than other immunosuppressants. Several randomized controlled trials (RCTs) have analyzed the role of MMF in patients with IgAN. We conducted this meta-analysis of all available RCTs to ascertain the benefits and risks of MMF treatment in comparison with placebos or steroids in patients with IgAN. <i>Methods:</i> The studies were identified by extended computer- based searches of the PubMed database (April, 2008) and the Cochrane Library, without language restriction. References in Medline-cited studies were reviewed to identify additional reports not indexed by Medline. RCTs comparing treatment of IgAN with mycophenolate against placebo or steroids were included in the analysis. <i>Results:</i> We identified 32 potentially relevant articles, but only 4 RCTs, which had enrolled a total of 168 patients, were included. Our meta-analysis demonstrated that MMF treatment did not have statistically significant effects in reducing proteinuria or protecting renal function in patients with IgAN. <i>Conclusion:</i> The currently available evidence does not support the routine use of MMF in patients with IgAN. Larger international collaborations should be put in place to further address this issue.